Biotech company Dynacure unveils IPO terms
12 July Dynacure, French biotechnology company, developing drugs for the treatment of neuromuscular diseases in the ½ phase of research, announced the terms of the upcoming IPO. Company headquartered in Ilkirsch-Graffenstaden, France, plans to attract 100 million dollars, releasing 6,3 million ADS at a cost of 15 to 17 Dollars.